Drug Topics
OCTOBER 12, 2023
A study presented at IDWeek 2023 showed significantly more patients in the treatment group were alive and oxygen-free by day 29 and day 60 compared to those in the placebo group.
Pharmacy Times
OCTOBER 12, 2023
Encorafenib (Braftovi; Pfizer Inc) and binimetinib (Mektovi; Pfizer Inc) approved for the treatment of patients with metastatic non-small cell lung cancer who harbor a BRAF V600E mutation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
OCTOBER 12, 2023
Family medicine physician Olusunmisola Oyesiku always thought she would practice in a big city, but after going through her family residency program at the University of Alabama in Selma, she ended up falling in love with rural medicine. The Selma program is one of a small, but growing, number of residencies in the country that places residents entirely in rural medical settings.
Fierce Healthcare
OCTOBER 12, 2023
Amazon’s $3.9 billion acquisition of One Medical made big waves when it was announced in July 2022, signaling that the online retailer had bold ambitions to expand its reach in healthcare. | One Medical CMO Dr. Andrew Diamond is bullish about what Amazon is building in healthcare. He believes Amazon Health can help tackle the burden of chronic diseases in the U.S.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
OCTOBER 12, 2023
Peter Marks wants drug developers to ask more stupid questions. It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances. Some companies are shelving programs or going out of business , even when they have promising data. The problems are numerous : The diseases are often exceptionally rare, limiting the potential market.
Fierce Healthcare
OCTOBER 12, 2023
Drugstore chain Walgreens plans to close 60 underperforming VillageMD clinics and exit five markets as part of an aggressive $1 billion cost-saving strategy as it looks to boost profitability in it | Drugstore chain Walgreens plans to close 60 underperforming VillageMD clinics and exit five markets as part of an aggressive $1 billion cost-reduction strategy as it looks to boost profitability in its healthcare business.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
OCTOBER 12, 2023
Videos on the social media platform where doctors used supportive language were found to improve attitudes towards Pap smears the most, a new study found.
STAT
OCTOBER 12, 2023
LONDON — European regulators on Thursday detailed their demands that Illumina divest the cancer diagnostics firm Grail, the latest fallout from the sequencing giant’s troubled 2021 acquisition. The move was just the most recent regulatory action against the deal. The European Commission in September 2022 ruled that the purchase violated antitrust rules, and Thursday’s order spelled out how the commission thought the deal’s unraveling should occur.
Fierce Healthcare
OCTOBER 12, 2023
Healthcare lobbying organizations’ efforts to carve out industry-specific exemptions in recently proposed Federal Trade Commission (FTC) policies are unlikely to see their requests reflected in the | FTC Chair Lina Khan told a conference of physicians that the proposal for a broad ban on non-compete clauses was largely supported in public comments, a sign that healthcare employers' requests for exemptions are unlikely to take root.
STAT
OCTOBER 12, 2023
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with data on biotech’s belt-tightening, the advance of xenotransplantation, and the escalating Ozempic panic.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
OCTOBER 12, 2023
Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses being the second pharmacist in IDSA history to receive a society award and what this means not only for her, but for the field.
Fierce Healthcare
OCTOBER 12, 2023
Wellvana, a value-based care enabler, is joining forces with AdventHealth as an exclusive partner to its primary care network in Florida. | AdventHealth is transitioning its entire primary care network in the state to value-based care for Medicare and Medicare Advantage patients. The partners’ goal is to improve clinical outcomes and lower the total cost of care.
Fierce Pharma
OCTOBER 12, 2023
Even as Teva Pharmaceuticals’ Icelandic counterpart Alvotech works to get its Reykjavik manufacturing facility back up to snuff, lingering problems at the plant—which derailed approval of the partn | The FDA shot down Alvotech and Teva's biosimilar candidate to Johnson & Johnson's Stelara over “certain deficiencies” uncovered by the FDA during a reinspection of the company's factory in Iceland earlier this year.
STAT
OCTOBER 12, 2023
When is a billion-dollar deal a bad omen? Has Wall Street gone overboard on Ozempic? And how do you edit a chicken? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss Bristol Myers Squibb’s multibillion-dollar acquisition of Mirati Therapeutics and what it means for a biotech sector still in a slump.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
OCTOBER 12, 2023
Pfizer is expanding the reach of its BRAF-MEK combo as the pharma giant looks to further build up its oncology presence. | Pfizer is expanding the reach of its BRAF-MEK combo as the pharma giant looks to further build up its oncology presence.
Fierce Healthcare
OCTOBER 12, 2023
By Theo Koury, MD, President, Vituity | Health systems are rethinking how they engage with patients and physician ownership is paving the way. Read on to break into innovation.
Fierce Pharma
OCTOBER 12, 2023
An apparent win for Novo Nordisk’s GLP-1 blockbuster Ozempic in chronic kidney disease (CKD) could herald a shift in how the condition has been treated for decades. | Based on the inclusion criteria for Novo Nordisk’s chronic kidney disease trial, dialysis bigwig DaVita believes there may only be “limited application” of the study’s findings to the overall CKD population.
Pharmacy Times
OCTOBER 12, 2023
Cassie Brunelle, PharmD and Pharmacist-in-Charge at Nurx discusses the role of the pharmacist, how the pharmacy profession has changed, and what is to come in the field.
Fierce Pharma
OCTOBER 12, 2023
After the FDA passed on an approval for mirikizumab in ulcerative colitis earlier this year because of manufacturing shortfalls, the Eli Lilly drug is gaining new momentum with a win in a phase 3 C | A majority of Crohn's disease patients experienced a clinical response and clinical remission after treatment with mirikizumab, the company said. The results provide a boost after mirikizumab's surprise manufacturing-related FDA rejection in April.
Pharmacy Times
OCTOBER 12, 2023
Investigators suggest that the Bacille Calmette–Guérin vaccine, which prevented tuberculosis in nonhuman primates infected with SIV, can also protect against HIV.
Drug Topics
OCTOBER 12, 2023
There has been growing evidence around the potential for the success of remote diabetes care and CGM technology use.
Pharmacy Times
OCTOBER 12, 2023
The president of HOPA discusses the importance of mentorship in oncology pharmacy as well as the value of HOPA’s mentorship initiatives.
STAT
OCTOBER 12, 2023
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Diabetes: Better shows data on app’s benefit with GLP-1s Better Therapeutics announced top-line data suggesting that its prescription app for diabetes treatment, AspyreRx, can boost the impact of GLP-1 diabetes treatments.
Fierce Pharma
OCTOBER 12, 2023
GSK has tapped Chongqing Zhifei to distribute Shingrix in China. BioNTech in-licensed a HER3 antibody-drug conjugate from Chinese company MediLink Therapeutics. | GSK has tapped Chongqing Zhifei to distribute Shingrix in China. BioNTech in-licensed a HER3 antibody-drug conjugate from Chinese company MediLink Therapeutics. The FDA rejected Biocon's proposed biosimilar version of Novo Nordisk's NovoLog—again.
PharmExec
OCTOBER 12, 2023
A discussion of the impact the new FDA SaMD guidance, identifying the differences between companion apps and SaMD, and what to expect from this combination in the future.
Pharmacy Times
OCTOBER 12, 2023
Contrary to earlier advice, new research suggests introducing infants to potential allergens early may reduce risk of developing allergies to those foods
Drug Store News
OCTOBER 12, 2023
School districts and organizations whose students will receive fresh produce coupons are in Florida, Louisiana, Maryland, Michigan, Mississippi, Missouri, Ohio and Pennsylvania.
Pharmacy Times
OCTOBER 12, 2023
Karline Peal, MBA of Vanderbilt Ingram Cancer Center discusses the positive impact technology has had in health care and how it can be implemented in the future.
European Pharmaceutical Review
OCTOBER 12, 2023
A new scheme from the Medicines and Healthcare products Regulatory Agency (MHRA) is set to cut the approval time for the lowest-risk clinical trials in the UK by over half. The new Notification Scheme is based on that outlined in the MHRA’s clinical trials consultation, which was endorsed by 74 percent of those who responded. It forms a significant part of the regulator’s overhaul of the clinical trials regulation announced in March 2023, which aims to make the UK a prime location for con
Pharmacy Times
OCTOBER 12, 2023
Larger institutions have continued to treat patients who needed carboplatin or cisplatin; however, the survey results don’t include smaller cancer centers that may face access challenges.
STAT
OCTOBER 12, 2023
Good morning, everyone, and welcome to another busy day. We are scrambling, in fact, to update our to-do list, schedule online calls, and sort out deadlines. To cope, we are quaffing several cups of stimulation, of course. Our choice today is maple bourbon. Meanwhile, here is the latest selection of interesting items for you to peruse. We hope your day is successful and productive.
Pharmacy Times
OCTOBER 12, 2023
Although education and training have historically been considered the primary factors influencing pay, the survey results challenge this notion.
Drug Store News
OCTOBER 12, 2023
Eligible Navitus members can now automatically access real-time comparative pricing at point of sale to improve affordability.
European Pharmaceutical Review
OCTOBER 12, 2023
Strong demand for small molecules as treatment for non-small cell lung cancer (NSCLC) in the eight major markets means that the small molecule treatment market for the disease is expected to reach over $15 billion by 2029. This represents approximately 40 percent of the total NSCLC market, stated GlobalData. Sales for AstraZeneca’s Tagrisso are anticipated to exceed $7 billion and hold a 48 percent share of the market of small molecules in lung cancer treatment by 2029, according to data and ana
Expert insights. Personalized for you.
144 
Let's personalize your content